Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

1. A compound, having a formula

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is an alkali metal salt, an alkaline earth metal salt, an ammonium salt, an amino acid salt, an amino sugar salt, or a tris salt.

3. The compound of claim 1 , wherein the compound is a mono-salt, or a di-salt.

4. The compound of claim 1 , wherein the alkyl phosphate is a mono- or di-sodium salt, mono- or di-potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, mono- or di-tris salt, ammonium salt, choline salt, or meglumine salt.

5. The compound of claim 1 , selected from:

I-18: 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl dihydrogen phosphate;

I-20: 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate disodium salt;

I-49: 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl dihydrogen phosphate tris salt;

I-107: sodium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen phosphate;

I-108: potassium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen phosphate;

I-109: potassium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate;

I-110: 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl dihydrogen phosphate arginine salt;

I-111: 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl dihydrogen phosphate choline salt;

I-112: ammonium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen phosphate;

I-113: 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl dihydrogen phosphate lysine salt;

I-114: 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl dihydrogen phosphate meglumine salt;

I-115: magnesium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate; or

I-116: Calcium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate.

6. A composition, comprising a compound according to claim 1 , and a pharmaceutically acceptable excipient.

7. A compound, wherein the compound is an organic base salt of a compound having a formula

8. The compound of claim 7 , wherein the organic base salt is a mono-salt, or a di-salt.

9. The compound of claim 7 , wherein the organic base salt is a tris salt.

10. The compound of claim 7 , wherein the organic base salt is an amino acid salt.

11. The compound of claim 7 , wherein the organic base salt is an arginine salt, lysine salt, mono-tris salt, di-tris salt, choline salt, or meglumine salt.

12. A compound, wherein the compound is an inorganic base salt of a compound having a formula

13. The compound of claim 12 , wherein the inorganic base salt is an alkali metal salt, an alkaline earth metal salt, or an ammonium salt.

14. The compound of claim 12 , wherein the inorganic base salt is a mono-salt, or a di-salt.

15. The compound of claim 12 , wherein the inorganic base salt is a mono-sodium salt, di-sodium salt, mono-potassium salt, di-potassium salt, calcium salt, magnesium salt, or mono-ammonium salt.

16. A spray-dried composition, comprising a polymer carrier and a compound having a formula

or a pharmaceutically acceptable salt thereof.

17. The spray-dried composition of claim 16 , wherein the spray-dried composition comprises from 1% to 50% w/w of the compound with respect to the carrier.

18. The spray-dried composition of claim 16 , wherein the polymer is a cellulose derivative, vinyl polymer, lactide polymer, sugar, or a combination thereof.

19. The spray-dried composition of claim 16 , wherein the composition is amorphous and/or has a glass transition temperature of from 100° C. to 120° C.

20. A method of making a spray-dried composition, comprising:

forming a mixture comprising a carrier, a solvent and a compound having a formula

or a pharmaceutically acceptable salt thereof; and

spray drying the mixture to form a spray-dried formulation comprising the compound and the carrier.

21. A method for treating a disease or condition for which an IRAK inhibitor is indicated, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a composition thereof, wherein the subject has a disease or condition selected from an auto-immune disease, inflammatory disorder, cardiovascular disease, neurodegenerative disorder, allergic disorder, multi-organ failure, kidney disease, platelet aggregation, cancer, transplantation, sperm motility, erythrocyte deficiency, graft rejection, lung injury, respiratory disease, ischemic condition, bacterial infection, viral infection, immune regulatory disorder or a combination thereof.

22. The method of claim 21 , further comprising administering a second therapeutic agent.

23. The method of claim 22 , wherein the second therapeutic agent is an analgesic, an antibiotic, an anticoagulant, an antibody, an anti-inflammatory agent, an immunosuppressant, a guanylate cyclase-C agonist, an intestinal secretagogue, an antiviral, anticancer, antifungal, or a combination thereof.